Creator: Help Dementia Editorial Team
Published: 2026-04-24T23:36:49

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

New study sits at the center of this dementia and brain health question.

Yes, new research confirms that Alzheimer’s disease can be slowed. Two FDA-approved medications—Leqembi (lecanemab) and Kisunla (donanemab)—are now proven to clear toxic amyloid-beta from the brain and slow cognitive decline in people with early-stage Alzheimer’s disease. Beyond pharmaceuticals, cognitive training and lifestyle interventions have demonstrated measurable benefits in clinical studies. While these advances don’t stop or reverse Alzheimer’s, they represent a fundamental shift: for the first time, we have evidence-based tools that meaningfully extend the period before cognitive decline accelerates.

The landscape of Alzheimer’s research has transformed dramatically in the past two years. We’re no longer simply managing symptoms. Studies show that people who engage in cognitive speed training can reduce their dementia risk by 25% over two decades. Others with lifelong mental stimulation see a 38% lower risk of Alzheimer’s and may delay diagnosis by approximately five years. Simultaneously, 138 drugs are now in 182 clinical trials, with three-quarters targeting the underlying biology of the disease rather than just its effects.

What Does “Slowing Alzheimer’s” Actually Mean?
FDA-Approved Treatments: How They Work and What to Expect
Cognitive Training: Building Mental Reserve Against Decline
Lifestyle Interventions: A Proven Path to Cognitive Protection
The Growing Clinical Trial Pipeline: Opportunities and Realities
A Molecular Breakthrough: The “Death Switch” and FP802
What These Discoveries Mean: A Shift from Inevitability to Actionability
Conclusion

What Does “Slowing Alzheimer’s” Actually Mean?

When researchers talk about slowing Alzheimer’s, they’re measuring cognitive decline over time—how quickly memory, thinking, and functional abilities deteriorate. In clinical trials, slowing might mean preserving mental sharpness for an additional six months, one year, or longer compared to untreated progression. For families facing Alzheimer’s diagnosis, this difference is profound: an extra year of recognizing grandchildren’s names, of maintaining conversation, of independence in daily life. The approved medications Leqembi and Kisunla work on a specific mechanism.

Both target amyloid-beta, a sticky protein that accumulates in the Alzheimer’s brain and is believed to damage neurons. By clearing this buildup, these drugs appear to slow the rate at which cognitive function declines. Clinical trials showed measurable cognitive benefit, though individual responses vary. It’s important to note that these treatments work best when given early—in the mild cognitive impairment or early dementia stage—before significant brain damage has occurred.

FDA-Approved Treatments: How They Work and What to Expect

Leqembi and Kisunla represent a new class of therapy called monoclonal antibodies. These laboratory-made proteins recognize amyloid-beta and bind to it, triggering the brain’s natural cleanup mechanisms. The medications are administered through regular infusions at medical centers, typically every two to four weeks. The clinical trial data is encouraging: patients on these drugs showed slowing of cognitive decline compared to those on placebo, though the absolute difference ranged from modest to more noticeable depending on the individual.

There are important limitations and tradeoffs to understand. Both medications require specific monitoring, including brain imaging (MRI) to watch for amyloid-related imaging abnormalities (ARIA), a potential side effect involving brain swelling or microhemorrhages. Some patients experience amyloid-related side effects that can be serious. Additionally, access remains limited—the infusions must be administered at specialized medical centers, not all insurance plans cover the medications equally, and ongoing research is still defining optimal dosing and patient selection. These treatments also work best when combined with other interventions like cognitive engagement and healthy lifestyle practices.

Cognitive Training: Building Mental Reserve Against Decline

One of the most compelling recent discoveries involves cognitive speed training—focused brain exercises designed to improve how quickly the mind processes information. Research published in 2026 by the National Institutes of Health found that adults 65 and older who completed five to six weeks of cognitive speed training showed a 25% lower rate of dementia diagnosis over the next two decades. This isn’t a marginal benefit; it’s a substantial reduction in lifelong dementia risk from a relatively brief intervention.

An even broader finding emerged in April 2026: individuals in the top 10% for lifelong cognitive engagement—those who regularly engaged their minds through reading, learning, conversation, hobbies, and mental challenges—had a 38% lower risk of Alzheimer’s and 36% lower risk of mild cognitive impairment. These people also tended to develop Alzheimer’s approximately five years later than those with the lowest mental stimulation. The implication is clear: building mental reserve throughout life—not just in the final years—creates a buffer against cognitive decline. Think of it like cardiovascular fitness; a heart strengthened through decades of exercise tolerates stress better than an untrained heart.

Cognitive Training: Building Mental Reserve Against Decline

Lifestyle Interventions: A Proven Path to Cognitive Protection

Beyond cognitive training, the broader category of lifestyle intervention shows real promise. The U.S. POINTER study, completed in 2025, was specifically designed to test whether accessible, sustainable healthy lifestyle changes could protect cognition in people at elevated Alzheimer’s risk. The answer was affirmative. The study examined factors including physical activity, cognitive engagement, diet quality, sleep, management of cardiovascular risk factors, and social engagement.

Participants who adopted these interventions showed measurable cognitive benefits. What makes the POINTER study particularly significant is its focus on accessibility and diversity. These weren’t cutting-edge experimental protocols; they were evidence-based practices that families could realistically adopt: regular walks, puzzles and reading, Mediterranean-style eating patterns, consistent sleep schedules, and social connection. Compared to medication infusions or intensive cognitive training programs, lifestyle changes are often free or low-cost, have no pharmaceutical side effects, and benefit overall health in multiple ways. The tradeoff, of course, is that lifestyle changes require sustained personal effort and motivation, whereas taking a medication is more passive. The ideal approach combines both: lifestyle as foundation, and medications when indicated.

The Growing Clinical Trial Pipeline: Opportunities and Realities

The sheer volume of Alzheimer’s research in progress should inspire cautious optimism. As of January 2025, 138 Alzheimer’s drugs were enrolled in 182 clinical trials worldwide. Most remarkably, 73% of these trials target the underlying biology of Alzheimer’s—the amyloid, tau, neuroinflammation, and other molecular mechanisms—rather than just treating symptoms. In 2025 alone, 48 Phase 1 trials tested 45 new drugs, nearly double the 26 Phase 1 trials and 25 drugs from 2024. However, there’s an important caveat: being in a clinical trial is not the same as having an approved, accessible treatment.

Many of these experimental drugs will fail. Some will show promise in early trials but not translate to larger populations. The path from Phase 1 to FDA approval typically takes many years. Additionally, most clinical trials recruit from major medical centers and universities; rural and underserved communities often have limited access. For families hoping a new drug might help a loved one with Alzheimer’s, understanding this pipeline’s reality—that hope and uncertainty coexist—is essential.

The Growing Clinical Trial Pipeline: Opportunities and Realities

A Molecular Breakthrough: The “Death Switch” and FP802

In March 2026, researchers made a discovery that illuminates the fundamental biology of Alzheimer’s. They identified a specific protein interaction—described as the “death switch”—that drives neurodegeneration in Alzheimer’s disease. This harmful interaction accelerates the toxic effects of amyloid and tau, speeding cognitive decline. Researchers then tested a compound called FP802 designed to disrupt this interaction.

In Alzheimer’s disease models (laboratory and animal studies), FP802 markedly slowed disease progression. While FP802 remains experimental and years away from human trials, this discovery is conceptually important. It demonstrates that even among the complex cascade of damage in Alzheimer’s, specific intervention points exist where disease can be interrupted. Researchers are now exploring whether multiple interventions targeting different points in the disease process—similar to how cancer therapy often combines several drugs—might be more effective than single-target approaches. For families, this suggests that even beyond the approved medications, the pipeline includes increasingly sophisticated tools.

What These Discoveries Mean: A Shift from Inevitability to Actionability

For decades, Alzheimer’s disease carried a sense of inevitability. Diagnosis meant a predictable decline, and families could do little except manage symptoms and plan for care. That narrative is changing. The convergence of approved medications, cognitive interventions, lifestyle research, and a swelling pipeline of new therapies means that Alzheimer’s is becoming a manageable condition—not curable yet, but increasingly controllable.

This shift carries both hope and responsibility. Hope, because tangible tools exist now to slow progression. Responsibility, because evidence-based approaches require action: early detection through cognitive assessment, engagement with healthcare providers, commitment to cognitive and physical activity, dietary attention, and sleep discipline. The future likely holds even more options as research continues. Within the next five years, expect additional FDA approvals, refined understanding of which patients benefit most from which treatments, and possibly combination therapies targeting multiple disease mechanisms simultaneously.

Conclusion

The evidence is clear: Alzheimer’s disease progression can be slowed through a combination of strategies. FDA-approved medications like Leqembi and Kisunla address amyloid pathology. Cognitive training reduces lifelong dementia risk by 25% or more. Lifestyle interventions protect cognition in diverse populations. And the research pipeline continues to expand, with new mechanisms of action being discovered and tested. None of these approaches offers a cure, but together, they shift the disease from inevitable decline to manageable progression.

If you or a loved one is concerned about cognitive health or facing Alzheimer’s diagnosis, the time to act is now. Discuss cognitive assessment with your healthcare provider. Ask about medication eligibility if diagnosed with early-stage disease. Prioritize activities that engage your mind, body, and social connections. The research from 2025 and 2026 shows that these steps genuinely matter—they can preserve mental function, delay diagnosis, and extend the years of independence and connection. Alzheimer’s remains serious, but it is no longer inevitable, and it is no longer without options.